Table 2 Modified LDLs, HDL composition and Lp-PLA2 activity in patients with type 2 diabetes and control subjects

Modified LDL

61.4 ± 20.0

78.6 ± 26.7 ^a

51.2 ± 19.3 ^a,b

0.005

2.17 ± 0.94

2.77 ± 1.41 ^a

1.85 ± 0.73 ^a,b

0.030

7.6 ± 3.5

7.7 ± 3.1

6.1 ± 2.0 ^a,b

0.017

HDL composition

17.1 ± 2.3

15.6 ± 3.0 ^a

17.3 ± 2.3 ^b

0.204

4.3 ± 1.7

6.7 ± 1.9 ^a

3.1 ± 1.0 ^a,b

<0.001

33.5 ± 4.3

31.3 ± 3.3 ^a

32.8 ± 3.7

0.076

31.9 ± 5.8

32.8 ± 6.3

34.3 ± 5.7 ^a,b

0.193

13.2 ± 3.4

13.6 ± 2.6

12.5 ± 2.9 ^a,b

0.265

1.1 ± 0.6

1.0 ± 0.6

1.0 ± 0.9

0.907

1.20 ± 0.28

1.19 ± 0.27

1.16 ± 0.27 ^a,b

0.539

2.61 ± 0.92

2.54 ± 0.81

2.98 ± 1.12 ^a,b

0.112

4.65 ± 2.19

2.57 ± 0.91

6.32 ± 2.68 ^a,b

<0.001

78.5 ± 25.5

82.6 ± 25.5

82.5 ± 23.1

0.152

Lp-PLA2 activity(μmol/min/mL)

20.1 ± 6.6

23.0 ± 7.2 ^a

19.1 ± 6.2 ^b

0.627

6.8 ± 2.7

7.1 ± 3.5

6.2 ± 2.6

0.995

13.3 ± 4.8

15.9 ± 4.6 ^a

12.9 ± 3.3 ^b

0.539

33.9 ± 10.5

30.9 ± 11.4 ^a

32.4 ± 10.6

0.510

66.1 ± 19.4

69.1 ± 21.2 ^a

67.6 ± 19.8

0.510